Smith & Nephew plc (NYSE:SNN – Get Rating) has received a consensus recommendation of “Buy” from the ten analysts that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $1,368.50.
A number of analysts have weighed in on the company. UBS Group upped their price target on Smith & Nephew from GBX 1,200 ($15.10) to GBX 1,295 ($16.30) in a research report on Friday, April 29th. Redburn Partners upgraded Smith & Nephew from a “sell” rating to a “neutral” rating in a research report on Friday, March 4th. StockNews.com lowered Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 12th. Royal Bank of Canada began coverage on Smith & Nephew in a research note on Tuesday, March 15th. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research raised Smith & Nephew from a “sell” rating to a “hold” rating in a research note on Friday.
A number of large investors have recently added to or reduced their stakes in the business. Signaturefd LLC lifted its stake in Smith & Nephew by 10.7% in the fourth quarter. Signaturefd LLC now owns 3,291 shares of the medical equipment provider’s stock valued at $114,000 after buying an additional 319 shares during the period. Harbor Investment Advisory LLC lifted its stake in Smith & Nephew by 21.8% in the first quarter. Harbor Investment Advisory LLC now owns 2,442 shares of the medical equipment provider’s stock valued at $78,000 after buying an additional 437 shares during the period. Highland Capital Management LLC lifted its stake in Smith & Nephew by 1.9% in the fourth quarter. Highland Capital Management LLC now owns 24,650 shares of the medical equipment provider’s stock valued at $853,000 after buying an additional 450 shares during the period. Veriti Management LLC increased its holdings in shares of Smith & Nephew by 7.7% in the fourth quarter. Veriti Management LLC now owns 6,336 shares of the medical equipment provider’s stock worth $219,000 after acquiring an additional 455 shares in the last quarter. Finally, Boston Common Asset Management LLC increased its holdings in shares of Smith & Nephew by 3.6% in the fourth quarter. Boston Common Asset Management LLC now owns 14,374 shares of the medical equipment provider’s stock worth $498,000 after acquiring an additional 503 shares in the last quarter. 26.03% of the stock is currently owned by hedge funds and other institutional investors.
The business also recently announced a semi-annual dividend, which was paid on Wednesday, May 11th. Shareholders of record on Friday, April 1st were paid a $0.288 dividend. This represents a yield of 2.3%. The ex-dividend date was Thursday, March 31st.
About Smith & Nephew (Get Rating)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.
- Get a free copy of the StockNews.com research report on Smith & Nephew (SNN)
- Texas Roadhouse Stock Looks Sizzling Down Here
- Two Stocks You Shouldn’t Buy On Post-Earnings Weakness
- Time to Bid Low for Farfetch Stock
- Don’t Wait Too Long to Buy These 3 Mega Caps
- Cheap Buys: These 3 Stocks are Now Trading Under $20
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.